Photo of Erman Akkus taken from mn.uio.no
Apr 11, 2024, 15:12
Erman Akkus: Prostate cancer screening: 2 studies of JAMA
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
”Prostate cancer screening: 2 studies of JAMA.
1. PSA screening and 15-year mortality. ‘CAP trial’.
- Screening vs standard practice, Prostate cancer-specific mortality: 0.69% vs 0.78%, RR: 0.92 (95% CI, 0.85-0.99) P = .03
- Detection of Gleason score ≤6, T1/T2 disease higher, but not gleason ≥7, T3, T4/N1/M1, tumors.
- All-cause deaths did not differ.
2. Screening with PSA, Kallikrein Panel, and MRI. ‘ProScreen trial’.
- Screening invitation vs not invatiation; screening by stepwise testing vs. not screening.
- 1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected by invitation.
- In invitation group: -Participants (screening group), low-grade cancer 0.41% and high-grade 1.65 %
-Not-participants, low-grade cancer 0.1% and high-grade 0.6%.”
Source: Erman Akkus/X
